📊 VTVT Key Takeaways
Is vTv Therapeutics Inc. (VTVT) a Good Investment?
vTv Therapeutics displays severely compromised operational fundamentals with a -100% YoY revenue collapse, indicating loss of primary business or divestiture of core assets. Net income appears driven by non-recurring gains rather than sustainable operations, but an exceptionally strong balance sheet ($98.1M cash, 0.01x debt-to-equity) provides substantial downside protection and runway for turnaround attempts.
vTv Therapeutics Inc. Key Strengths (VTVT)
- Fortress balance sheet with $98.1M cash reserves and minimal $8.9M liabilities
- Debt-free capital structure (0.01x debt-to-equity) with exceptional liquidity (14.36x current ratio)
- Positive operating and free cash flow of $9.2M despite revenue collapse suggests underlying asset value
VTVT Stock Risks: vTv Therapeutics Inc. Investment Risks
- Catastrophic -100% YoY revenue decline reflects complete loss of primary business or product commercialization failure
- Reported profitability metrics are artificially inflated by non-recurring items; sustainable operating income is unclear
- Pharmaceutical sector with zero operational revenue suggests either shell status post-acquisition/divestiture or failed pipeline strategy
Key Metrics to Watch
- Revenue trajectory and new product/asset acquisition announcements indicating turnaround strategy
- Operating cash flow sustainability and cash burn rate relative to $98.1M cash runway
- Breakdown of net income components to isolate recurring operational profitability from one-time gains
vTv Therapeutics Inc. (VTVT) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The 24.8% free cash flow margin provides substantial flexibility for dividends, buybacks, and strategic investments. Strong liquidity with a 14.36x current ratio provides a solid financial cushion.
VTVT Profit Margin, ROE & Profitability Analysis
VTVT vs Healthcare Sector: How vTv Therapeutics Inc. Compares
How vTv Therapeutics Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is vTv Therapeutics Inc. Stock Overvalued? VTVT Valuation Analysis 2026
Based on fundamental analysis, vTv Therapeutics Inc. appears fundamentally strong relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
vTv Therapeutics Inc. Balance Sheet: VTVT Debt, Cash & Liquidity
VTVT Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: vTv Therapeutics Inc.'s revenue has declined by 84% over the 5-year period, indicating business contraction.
VTVT Revenue Growth, EPS Growth & YoY Performance
VTVT Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | N/A | -$5.1M | N/A |
| Q3 2025 | N/A | -$4.8M | N/A |
| Q2 2025 | N/A | -$5.2M | N/A |
| Q1 2025 | N/A | -$4.9M | N/A |
| Q3 2024 | N/A | -$4.8M | N/A |
| Q2 2024 | N/A | -$5.2M | N/A |
| Q1 2024 | N/A | -$4.5M | N/A |
| Q3 2023 | N/A | -$4.3M | N/A |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
vTv Therapeutics Inc. Dividends, Buybacks & Capital Allocation
VTVT SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for vTv Therapeutics Inc. (CIK: 0001641489)
📋 Recent SEC Filings
❓ Frequently Asked Questions about VTVT
What is the AI rating for VTVT?
vTv Therapeutics Inc. (VTVT) has an AI grade of B with 62% confidence, based on fundamental analysis of SEC EDGAR filings.
What are VTVT's key strengths?
Claude: Fortress balance sheet with $98.1M cash reserves and minimal $8.9M liabilities. Debt-free capital structure (0.01x debt-to-equity) with exceptional liquidity (14.36x current ratio).
What are the risks of investing in VTVT?
Claude: Catastrophic -100% YoY revenue decline reflects complete loss of primary business or product commercialization failure. Reported profitability metrics are artificially inflated by non-recurring items; sustainable operating income is unclear.
What is VTVT's revenue and growth?
vTv Therapeutics Inc. reported revenue of $36.8M.
Does VTVT pay dividends?
vTv Therapeutics Inc. does not currently pay dividends.
Where can I find VTVT SEC filings?
Official SEC filings for vTv Therapeutics Inc. (CIK: 0001641489) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is VTVT's EPS?
vTv Therapeutics Inc. has a diluted EPS of $0.00.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is VTVT's fundamental grade?
Based on our AI fundamental analysis in June 2026, vTv Therapeutics Inc. has a B grade with 62% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is VTVT stock overvalued or undervalued?
Valuation metrics for VTVT: ROE of 26.8% (sector avg: 15%), net margin of 65.5% (sector avg: 12%). Higher ROE suggests strong returns relative to peers.
What is VTVT's AI grade for 2026?
Our dual AI analysis gives vTv Therapeutics Inc. a combined B grade for 2026. Revenue is data pending, with profitability above sector average. Always conduct your own research.
What is VTVT's free cash flow?
vTv Therapeutics Inc.'s operating cash flow is $9.2M, with capital expenditures of $0.0. FCF margin is 24.8%.
How does VTVT compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin 65.5% (avg: 12%), ROE 26.8% (avg: 15%), current ratio 14.36 (avg: 2).
Why is VTVT's return on equity (ROE) so high?
vTv Therapeutics Inc. has a return on equity of 26.8%, significantly above the Healthcare sector average of 15%. A high ROE indicates the company is efficient at generating profits from shareholder equity. This is supported by a 65.5% net margin.